Lyell Immunopharma, Inc. Quarterly Retained Earnings (Accumulated Deficit) in USD from Q4 2020 to Q2 2025

Taxonomy & unit
us-gaap: USD
Description
The cumulative amount of the reporting entity's undistributed earnings or deficit.
Summary
Lyell Immunopharma, Inc. quarterly Retained Earnings (Accumulated Deficit) history and growth rate from Q4 2020 to Q2 2025.
  • Lyell Immunopharma, Inc. Retained Earnings (Accumulated Deficit) for the quarter ending June 30, 2025 was -$1.44B, a 29.9% decline year-over-year.
Retained Earnings (Accumulated Deficit), Quarterly (USD)
Retained Earnings (Accumulated Deficit), YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q2 2025 -$1.44B -$331M -29.9% Jun 30, 2025 10-Q 2025-08-12
Q1 2025 -$1.4B -$335M -31.5% Mar 31, 2025 10-Q 2025-05-13
Q4 2024 -$1.35B -$343M -34.2% Dec 31, 2024 10-Q 2025-08-12
Q3 2024 -$1.15B -$204M -21.5% Sep 30, 2024 10-Q 2024-11-07
Q2 2024 -$1.11B -$210M -23.4% Jun 30, 2024 10-Q 2024-08-07
Q1 2024 -$1.06B -$228M -27.4% Mar 31, 2024 10-Q 2024-05-06
Q4 2023 -$1B -$235M -30.6% Dec 31, 2023 10-K 2025-03-11
Q3 2023 -$949M -$190M -25% Sep 30, 2023 10-Q 2023-11-07
Q2 2023 -$898M -$210M -30.4% Jun 30, 2023 10-Q 2023-08-08
Q1 2023 -$834M -$182M -27.9% Mar 31, 2023 10-Q 2023-05-04
Q4 2022 -$767M -$183M -31.3% Dec 31, 2022 10-K 2024-02-28
Q3 2022 -$759M -$258M -51.6% Sep 30, 2022 10-Q 2022-11-08
Q2 2022 -$689M -$237M -52.5% Jun 30, 2022 10-Q 2022-08-04
Q1 2022 -$653M Mar 31, 2022 10-Q 2022-05-10
Q4 2021 -$584M -$250M -74.9% Dec 31, 2021 10-K 2023-02-28
Q3 2021 -$501M Sep 30, 2021 10-Q 2021-11-12
Q2 2021 -$452M Jun 30, 2021 10-Q 2021-08-12
Q4 2020 -$334M Dec 31, 2020 10-K 2022-03-29
* An asterisk sign (*) next to the value indicates that the value is likely invalid.